Author contributions
HG Choi, JH W and SY Kim organized and analyzed the data and prepared the manuscript. HI Kim and JY Park interpreted the results of analyzing data. SH Park made some instruction in the study. YI Hwang, SH Jang, and KS Jung worked in the writing and critical review of the manuscript. HG Choi participated in the preparation of the manuscript. JH Kim designed the study and reviewed the manuscript.
To the Editor,
Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, posing a serious public health problem. The prevalence of asthma in COVID-19 patents differs among studies, with 0.9% reported in Wuhan, China, and markedly higher prevalence rates of 9% and 14% reported in the United States (US) and the United Kingdom (UK), respectively.1-3 Data from the UK showed that asthma was a risk factor for severe COVID-19; however, another study from the US showed no association between asthma and severe disease, suggesting that it is still unclear whether asthma is a risk factor for a poor prognosis.4,5
Given the variability in the reports analysing the impact of underlying asthma on the prevalence and severity of COVID-19, there is a need to better characterize the relationship between asthma and COVID-19. The Korea Centers for Disease Control and Prevention (KCDC) has collected clinical data from hospitalized patients with mild to critical COVID-19 nationwide using a standardized clinical record form.6Using this dataset, we evaluated the association between a history of asthma and mortality and morbidity related to COVID-19. A Cox proportional hazards regression model was used for mortality, and a linear regression model was used for morbidity scores.
In this study population, 2.3% (n=96) of the patients were diagnosed with comorbid COVID-19 and asthma, while most (n=3,961) did not have asthma (Table 1). The mortality rate was 8.3% (8/96) in patients with asthma and 3.0% (118/3,961) in those without asthma (p=0.009). The relative HR for mortality in participants with asthma compared with those without asthma was 2.48 (95% CI =1.21-5.08, p=0.013). After adjustment for multiple variables, the risk of mortality was 2.20 (95% CI =1.02-4.76, p=0.045) in patients with asthma compared with those without asthma (Table 2). Subgroup analyses based on past medical history showed that among the patients with asthma, those with heart failure and chronic heart disease had an elevated risk of mortality (HR=31.61, 95% CI=4.36-229.05, p<0.001; HR=4.68, 95% CI=1.30-16.84, p=0.018, respectively, Table S1). To assess the effect of asthma on the clinical morbidity due to COVID-19, the maximum morbidity score was obtained, and this score was used to calculate the EV for morbidity. COVID-19 patients with asthma had a higher maximum morbidity score than those without asthma (EV = 0.44, 95% CI = 0.16-0.73, p=0.003), indicating that asthma participants ranked 0.44 points higher than non-asthma participants (Table S2 and S3).
These data differ from those reported in previous studies, possibly because of the different health care systems in each country and the different characteristics of the study participants. Earlier in 2020, many countries lacked sufficient hospital beds and physicians; however, the initial peak surge in cases during the COVID-19 pandemic did not exceed the capacity of the health care system; during this period, ~10,000 patients were infected among ~50,000,000 Koreans. The registry used in this study includes COVID-19 patients across the spectrum of disease severity, unlike other studies, which mostly included severely hospitalized patients.2,5 As all COVID-19 patients are isolated, even those with mild cases, we postulate that the impact of host factors such as underlying diseases may be relatively greater on the outcomes.
In conclusion, our study provides strong evidence that asthma is associated with an increased risk of mortality and worse clinical outcomes in patients with COVID-19.